We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
-0.88%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$227M
AUM Growth
-$15.9M
Cap. Flow
-$6.57M
Cap. Flow %
-2.89%
Top 10 Hldgs %
7.9%
Holding
407
New
8
Increased
60
Reduced
329
Closed
10

Top Buys

Rank Stock Value
1
XFLT
XAI Floating Rate & Alternative Income Trust
XFLT
+$689K
2
VTA
INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND
VTA
+$551K
3
FRA icon
BlackRock Floating Rate Income Strategies Fund
FRA
+$468K
4
ENIC icon
Enel Chile
ENIC
+$430K
5
EFT
Eaton Vance Floating-Rate Income Trust
EFT
+$429K

Top Sells

Rank Stock Value
1
GRA
W.R. Grace & Co.
GRA
+$1.73M
2
BGX
Blackstone Long-Short Credit Income Fund
BGX
+$731K
3
BGB
Blackstone Strategic Credit 2027 Term Fund
BGB
+$693K
4
NOA
North American Construction
NOA
+$554K
5
MCI
Barings Corporate Investors
MCI
+$524K

Sector Composition

Rank Sector Weight
1 Healthcare 25.28%
2 Real Estate 19.7%
3 Energy 13.28%
4 Utilities 12%
5 Materials 10.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABCL icon
301
AbCellera Biologics
ABCL
$1.62B
$174K 0.08%
8,664
-447
-5% -$7.9K
ARQT icon
302
Arcutis Biotherapeutics
ARQT
$3.55B
$174K 0.08%
7,304
-388
-5% -$8.85K
FLNA
303
Filana Therapeutics
FLNA
$42.7M
$174K 0.08%
2,798
-153
-5% -$12.8K
CRDF icon
304
Cardiff Oncology
CRDF
$63.6M
$172K 0.08%
25,770
-1,344
-5% -$8.44K
IMVT icon
305
Immunovant
IMVT
$7.99B
$172K 0.08%
19,794
-1,033
-5% -$9.32K
KRYS icon
306
Krystal Biotech
KRYS
$10.7B
$172K 0.08%
3,288
-167
-5% -$9.89K
INO icon
307
Inovio Pharmaceuticals
INO
$84.7M
$171K 0.08%
1,988
-104
-5% -$10.4K
SRNE
308
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$171K 0.08%
22,465
-1,181
-5% -$10K
KRON
309
DELISTED
Kronos Bio
KRON
$170K 0.07%
8,126
-428
-5% -$9.19K
KURA icon
310
Kura Oncology
KURA
$826M
$170K 0.07%
9,091
-481
-5% -$9.06K
RPTX
311
DELISTED
Repare Therapeutics
RPTX
$170K 0.07%
6,482
-346
-5% -$11.2K
RVMD icon
312
Revolution Medicines
RVMD
$39.1B
$169K 0.07%
6,150
-321
-5% -$9.34K
AKBA icon
313
Akebia Therapeutics
AKBA
$341M
$168K 0.07%
58,243
-3,041
-5% -$8.68K
ANNX icon
314
Annexon
ANNX
$814M
$168K 0.07%
9,043
-472
-5% -$9.57K
BTAI icon
315
BioXcel Therapeutics
BTAI
$26.1M
$168K 0.07%
347
-17
-5% -$7.47K
PSTX
316
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$168K 0.07%
23,082
-1,205
-5% -$10.3K
SWTX
317
DELISTED
SpringWorks Therapeutics
SWTX
$167K 0.07%
2,640
-134
-5% -$10.3K
BOLT icon
318
Bolt Biotherapeutics
BOLT
$7.72M
$165K 0.07%
651
-34
-5% -$9.61K
RAPT
319
DELISTED
RAPT Therapeutics
RAPT
$165K 0.07%
664
-35
-5% -$9.25K
SGMO
320
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$163K 0.07%
18,086
-951
-5% -$9.4K
ZYME icon
321
Zymeworks
ZYME
$1.66B
$163K 0.07%
5,597
-297
-5% -$9.87K
CMPS
322
Compass Pathways
CMPS
$1.46B
$162K 0.07%
5,439
-285
-5% -$9.56K
CLVS
323
DELISTED
Clovis Oncology, Inc.
CLVS
$162K 0.07%
36,410
-1,893
-5% -$9.12K
SYRS
324
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$161K 0.07%
3,609
-189
-5% -$9.23K
KDNY
325
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$161K 0.07%
12,632
-667
-5% -$8.78K
11 12
13
14 15

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
RC
Roubaix Capital Denver, Colorado $214M AUM 32.43% 1-Year Est. Return

Virtus ETF Advisers's Q3 2021 Portfolio in Review

As of Q3 2021, Virtus ETF Advisers held 407 positions worth $227M, down 6.5% from $243M the previous quarter. Its ten largest holdings account for 7.9% of the portfolio.

Trading was light in Q3 2021: portfolio turnover was 4.4%. Virtus ETF Advisers opened 8 new positions and exited 10, leaving the 407-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 25% of assets, down from 27% a quarter earlier, followed by Real Estate and Energy.

  • Virtus ETF Advisers's largest Q3 2021 buy was XAI Floating Rate & Alternative Income Trust: 15,447 shares worth $663K.
  • Virtus ETF Advisers added most to Enel Chile in Q3 2021, an estimated $430K increase.
  • Virtus ETF Advisers's biggest Q3 2021 reduction was North American Construction, cutting an estimated $554K.
  • Virtus ETF Advisers fully exited W.R. Grace & Co. in Q3 2021, selling an estimated $1.73M.
  • Virtus ETF Advisers's ten largest holdings make up 7.9% of its $227M portfolio in Q3 2021.
  • Virtus ETF Advisers opened 8 new positions and closed 10 in Q3 2021.
  • Virtus ETF Advisers's portfolio value fell 6.5% quarter-over-quarter to $227M.

Based on Virtus ETF Advisers's 13F filing for Q3 2021, filed 15 Nov 2021.